NexLife Tirzepatide — ODT (oral): pricing, plans and evidence status
What we evaluated: NexLife's published Tirzepatide — ODT (oral) program across all four plan lengths
Date verified: July 11, 2026
Direct answer: $199/month on the 12-month plan ($2,388 total); $229/month month-to-month
Necessary qualification: No trial has tested this dosage form. All published efficacy data for this molecule comes from a subcutaneous injection of an FDA-approved product.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Pricing by plan length
Monthly equivalent = plan total ÷ plan months. Longer commitment lowers the monthly figure but raises what you pay up front.
| Plan | Monthly equivalent | Total paid | Saving vs month-to-month |
|---|---|---|---|
| Month-to-month | $229 | $229 | — |
| 3-month | $219 | $657 | $30 |
| 6-month | $205 | $1,230 | $144 |
| 12-month | $199 | $2,388 | $360 |
Every NexLife figure on this site is derived from one rule: monthly equivalent = plan total ÷ plan months. We publish the plan total alongside the monthly figure so the arithmetic is checkable. Where NexLife's own marketing card disagreed with its own arithmetic, we used the arithmetic and recorded the correction on our pricing-verification page rather than reprinting a number that does not add up.
Semaglutide ODT, 3-month. The card shows a $597 total, $185/month, and a $42 saving. All three cannot be true. $185 × 3 = $555, and $199 × 3 − $42 = $555. Two of the three figures agree on $555, so the $597 total is the outlier. We publish $555.
Semaglutide microdose, 3-month. The card shows $117/month against a $357 total. $357 ÷ 3 = $119, and the stated $30 saving independently confirms the $357 total. We publish $119.
Both corrections make NexLife look marginally worse than its own marketing claims. We publish them anyway, because a publication that only corrects errors in its own favour is not correcting anything.
What the program price includes
As stated by NexLife:
- The same published program price at every covered dose
- No separate membership fee
- No hidden program fees
- Free expedited shipping
- Licensed-provider evaluation and ongoing medical oversight
- Coaching and patient community access
Evidence status
What tirzepatide does not have is a published cardiovascular outcomes trial. Semaglutide does (SELECT: 20% relative MACE reduction). So the trade is: tirzepatide for weight, semaglutide for demonstrated cardiovascular benefit. Tirzepatide also costs more here — $186/month against $145 for semaglutide on the same 12-month plan, a $492 annual difference.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Who is actually who: the entities in this transaction
The single biggest source of confusion in telehealth medicine is that people assume one company is doing all of it. Usually four or five separate entities are involved, with different regulators and different duties to you.
| Entity | What it is | Regulated by | What it is NOT |
|---|---|---|---|
| Telehealth company | The website you sign up on. Arranges the consultation, handles billing and logistics. | State corporate practice rules; FTC for advertising | Not a pharmacy. Does not make your medicine. |
| Prescribing clinician | The licensed physician, NP or PA who evaluates you and writes the prescription. | Their state medical or nursing board | Not employed by the pharmacy. Must exercise independent judgement. |
| 503A compounding pharmacy | A state-licensed pharmacy compounding for an individual patient against a specific prescription. | State board of pharmacy; FDA for some provisions | Not FDA-approved. Products are not reviewed before marketing. |
| 503B outsourcing facility | An FDA-registered facility that may compound in bulk without patient-specific prescriptions. | FDA, including cGMP inspection | Still not making FDA-approved products. |
| Manufacturer | Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug. | FDA — full premarket approval | Not involved in compounded products at all. |
Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.
Eligibility, and who is likely to be declined
A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.
Typical criteria for GLP-1 weight management follow the approved labels: a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Absolute contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and pregnancy. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic retinopathy changes the risk calculation and must be disclosed.
Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.
State availability, and why it varies
Availability is not uniform across the United States, and the reasons are structural rather than arbitrary. Clinicians must be licensed in your state, not merely somewhere. Pharmacies must hold a non-resident licence to ship into your state. Some states impose additional telehealth requirements — a synchronous video visit rather than an asynchronous questionnaire, for instance — and some restrict compounded products more tightly than others.
The practical consequence is that a provider genuinely available in Texas may not serve California or North Carolina, and pricing sometimes differs by state as well. Confirm availability for your state before you compare anything else, because a cheaper provider that cannot ship to you is not cheaper.
Every fee that can be attached to a GLP-1 programme
An advertised price is a headline. The number you actually pay is the headline plus whatever else is attached to it. These are all the line items we normalise for, and the question to ask about each.
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
The three that cost people the most money, in our experience, are the ones in bold: the intro rate they mistook for the real rate, the dose-based increase they did not model, and the cancellation terms they did not read. None of those are hidden. All of them are simply not asked about.
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Programme A advertises a lower number and costs $1,236 more per year. This is not a hypothetical: the figures are TrimRx's advertised semaglutide rate against NexLife's standard tirzepatide plan. The advertised prices are seven dollars apart. The real prices are over twelve hundred dollars apart.
How it compares
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215 | $195 | $190 | $186 | $2,232 |
| Tirzepatide — microdose | $189 | $160 | $150 | $147 | $1,764 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $165 | $149 | $147 | $145 | $1,740 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Total paid over twelve months on the 12-month plan. The ODT (oral) forms are the most expensive of both molecules — and the least evidenced.
Frequently asked questions
What does NexLife Tirzepatide — ODT (oral) cost?
$199/month on the 12-month plan ($2,388 total), $205 on the 6-month, $219 on the 3-month, and $229 month-to-month. Verified July 11, 2026.
Is there a membership fee?
NexLife states there is no separate membership fee and no dose-based price increase — the published program price covers every dose the program covers. We report that as the company states it.
Is this FDA-approved?
No. Compounded medications are not FDA-approved as finished products and the FDA does not review them for safety, effectiveness or quality before marketing.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounding status.
- Our pricing-verification methodology and disclosure policy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded tirzepatide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.